$CANF

Can-Fite BioPharma (NYSE American: CANF) said it is advancing Phase III programs for Piclidenoson and Namodenoson under FDA and EMA frameworks. Namodenoson is in a pivotal Phase III study for advanced liver cancer (HCC) with Child-Pugh B7 cirrhosis, with FDA Fast Track and orphan designations. Piclidenoson is in Phase III for moderate-to-severe plaque psoriasis.

Can-Fite BioPharma (NYSE American: CANF) said Australia’s Patent Office allowed Patent Application No. 2021290439 for “Treatment of Advanced Metastatic Cancer.” The company said the patent supports its Namodenoson program, including a Phase 3 pivotal study in advanced hepatocellular carcinoma and a planned Phase 2b with gemcitabine in pancreatic cancer.

Can-Fite BioPharma (CANF) said it completed enrollment for the interim analysis of its pivotal Phase 3 trial of piclidenoson in moderate-to-severe plaque psoriasis. The randomized, double-blind study enrolled 247 patients; results are expected Q4 2026–Q1 2027. Co-primary endpoints are PASI 75 and sPGA 0/1 at Week 16. CANF shares closed July 2 at $3.91.

Can-Fite BioPharma Ltd. (CANF) shares rose about 37% after the company reported positive Phase 2a safety results for its pancreatic cancer drug candidate Namodenoson. The stock was quoted around $4.06, up $1.09, after opening at $5.02 following a $2.97 close.

Can-Fite Biopharma (AMEX:CANF) reported updated survival and safety results for namodenoson in an open-label pancreatic cancer trial (20 patients; progressed after standard therapies). In the third-line cohort (8 evaluable), median overall survival exceeded 5 months; 62.5% lived ≥5 months and 37.5% ≥7 months. Company said the drug was well tolerated and plans a Phase 2b combo with chemotherapy.

Can-Fite BioPharma (NYSE American: CANF) reported Phase 2a results for Namodenoson in advanced pancreatic ductal adenocarcinoma. In an open-label study of 20 patients, it met the primary safety endpoint and showed durable survival in a third-line subgroup: median OS >5 months; 62.5% alive at 5 months; 37.5% at 7 months. Can-Fite plans a Phase 2b chemo-combination study.

Can-Fite BioPharma (NYSE American: CANF) reported encouraging clinical observations from its ongoing Phase 2a pancreatic cancer study of namodenoson as monotherapy, with enrollment completed and some patients showing prolonged disease control, including one on therapy for ~16 months. The company also said ASCO 2026 materials support namodenoson’s RAS-pathway inhibition mechanism, alongside preclinical effects on Wnt/β-catenin and NF-κB.

D. Boral Capital upgraded Can-Fite BioPharma (CANF) to Buy from Hold, setting a price target of $7.00 due to progress in its oncology pipeline, specifically the advancement of Namodenoson into a Phase 2b pancreatic cancer study. The previous downgrade was attributed to a reverse stock split, not clinical deterioration. Can-Fite recently reported a net loss for 2025 but announced positive Phase 2a results for namodenoson in pancreatic cancer and received an Israeli patent for A3 adenosine receptor agonists for obesity.

Can-Fite BioPharma Ltd. announced it has entered into a definitive agreement for the immediate exercise of warrants, expected to generate approximately $4.0 million in gross proceeds. These funds will be allocated towards research and development, clinical trials, and general corporate purposes. The company will also issue new unregistered warrants as part of the transaction.

Can-Fite BioPharma's shares surged after its drug, Namodenoson, met the primary endpoint in a Phase 2a study for pancreatic cancer, demonstrating improved overall survival rates and a favorable safety profile. The company is also exploring the drug's efficacy in liver cancer and received a Canadian patent for its use as an anti-obesity therapy. Topline efficacy data for pancreatic cancer is expected in Q3 2026, and its stock is trading near its 52-week low.